Should I buy Helmerich & Payne, Inc. (HP) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Helmerich & Payne, Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Guggenheim | 80 % | +18.4 % | 5 | $80 +89% |
| Jefferies | 54 % | +11.6 % | 13 | $45 +6% |
| RBC Capital | 45 % | +10.5 % | 11 | $40 -6% |
| Citigroup | 44 % | +2.3 % | 16 | $36 -15% |
| Morgan Stanley | 58 % | -3.0 % | 19 | $41 -3% |
| JP Morgan | 43 % | -5.7 % | 7 | $34 -20% |
| Susquehanna | 36 % | -5.8 % | 14 | $44 +4% |
| Barclays | 17 % | -17.8 % | 6 | $50 +18% |
✅ Reasons to believe
- Few solid positives from analysts right now: of 7 ratings, only 3 buys, and the median price target ($41) is -3% below the price ($42). Caution prevails.
⚠️ Reasons to hesitate
- Even the most reliable firm on HP, Morgan Stanley (58% hit rate, 19 scored calls), only targets $41 (call made on August 20, 2026, maturing on August 20, 2027) (-3%) in its most recent call, and $23 (call made on November 25, 2025, maturing on November 25, 2026) (-46%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 7 ratings, 3 are neutral and 1 is a sell.
- Limited upside: the median target is only -3% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- Volatile stock: sharp swings — including steep drops — are part of its profile.
- No dividend: your return depends only on price appreciation.
The analyst consensus on HP
Median target $41 (-3%) · 7 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Helmerich & Payne, Inc. now?
We won't decide for you. The facts: 43% of analysts rate it a buy, median target $41 (-3%), and Morgan Stanley (most reliable on HP, 58%) targets $41. Weigh that against valuation and volatility. This is not personalized advice.
Is it too late to invest in Helmerich & Payne, Inc.?
The stated upside is small: the median target ($41) sits just -3% from the price ($42) (most reliable on HP: Morgan Stanley, 58%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Helmerich & Payne, Inc. still worth investing in?
It depends on the gap between the price ($42) and its estimated value: analysts target $41 on median (-3%), with 43% buys (most reliable on HP: Morgan Stanley, 58%). Cross-check with their real reliability on HP and the cautions above. Information, not advice.
What's the main risk in buying HP?
Even the most reliable firm on HP, Morgan Stanley (58% hit rate, 19 scored calls), only targets $41 (call made on August 20, 2026, maturing on August 20, 2027) (-3%) in its most recent call, and $23 (call made on November 25, 2025, maturing on November 25, 2026) (-46%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Helmerich & Payne, Inc. profile (consensus, analyst reliability, price target, performance).